Compass Therapeutics (CMPX) Retained Earnings (2018 - 2026)

Compass Therapeutics has reported Retained Earnings for 9 years, with the latest figure at -$159000.0 in Q1 2026.

• Quarterly Retained Earnings fell 183.68% year-over-year to -$159000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$159000.0 (down 183.68% YoY) and the FY2025 annual result came in at $280000.0, up 33.33% from the prior year.
• Retained Earnings retreated to -$159000.0 in Q1 2026 per CMPX's latest filing, from $280000.0 in the prior quarter.
• Over five years, Retained Earnings peaked at $280000.0 in Q4 2025 and troughed at -$349.7 million in Q3 2024.
• A 5-year average of -$90.3 million and a median of -$302000.0 in 2022 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings sank 223252.74% in 2024, then surged 328.57% in 2025.
• Over 5 years, Retained Earnings stood at -$302000.0 in 2022, then tumbled by 104306.62% to -$315.3 million in 2023, then soared by 100.07% to $210000.0 in 2024, then jumped by 33.33% to $280000.0 in 2025, then sank by 156.79% to -$159000.0 in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$159000.0, $280000.0, and $274000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.